Lindsay Davies

Lindsay Davies is the Chief Scientific Officer of NextCell Pharma in Stockholm, Sweden. Lindsay is an SME in mesenchymal stromal cell biology and cell therapy, having worked in the field for the last 20 years. She completed her PhD in orthopaedic biochemistry at Cardiff University in the UK, focussing on cell therapy for cartilage repair; springboarding her into a career in stem/stromal cell biology within the UK. She subsequently moved to Karolinska Institutet, Sweden and as an Associate Professor Dr Davies worked with basic science and clinical trial development using stromal cells from different tissue sources.

In 2020, Dr Davies joined NextCell Pharma, a cell therapy company, developing stromal cell products for usage in multiple clinical indications. She has supported the company´s movement from a Phase I company, with one initial clinical trial to four active Phase I/II trials, international expansion, and a Phase III clinical trial and commercialisation programme in development.

Dr Davies continues to work closely with academia in cell therapy development. In addition to her academic and industrial roles, Lindsay has recently been appointed as European Secretary for the International Society for Cell and Gene Therapy, sitting on the European Task Force and several committees related to process development and commercialisation.